Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Common side effects include fluid retention, nausea, vomiting, myalgia, fatigue, and asthenia.What Side Effects May Be Caused by Capmatinib?In addition to its intended effects, a m···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：31
Capmatinib inhibits c-Met, a type of tyrosine kinase that plays a role in embryonic development, organ formation and wound healing, but is also involved in the initiation and progr···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：32
Capmatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor mutations that cause MET exon ···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：30
Capmatinib is the first therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) harboring a specific mutation, namel···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：26
Capmatinib (brand name: Capmatinib) is an anticancer drug indicated for the treatment of metastatic non-small cell lung cancer (NSCLC). The tumors in such NSCLC patients harbor a s···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：29
Capmatinib is indicated for the treatment of lung cancer. Its mechanism of action is to block a protein that causes cancer cell growth and proliferation, thereby helping to slow do···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：37
Capmatinib is indicated for the treatment of a specific type of non-small cell lung cancer (NSCLC). It helps inhibit the growth and proliferation of certain cancer cells.What are t···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：84
Capmatinib is an antineoplastic agent (cancer medication). It works by interfering with the growth of cancer cells, ultimately leading to their destruction.2026 Latest Price of Cap···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：27
Capmatinib is indicated for the treatment of metastatic (spread) non-small cell lung cancer (NSCLC) in patients whose tumors harbor abnormal mesenchymal-epithelial transition facto···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：31
On February 11, 2020, Novartis announced that the U.S. Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for the MET inhibitor capmatinib (INC280) and ···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：29
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Tepotinib™ (Capmatinib, formerly known as INC280), an oral MET inhibitor, for···【more】
Article source：Captain MedicineRelease date：2026-01-09Recommended：28
Trametinib (Mekinist) is a targeted therapy indicated for the treatment of unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. As a prescription-only medic···【more】
Article source：Captain MedicineRelease date：2026-01-08Recommended：28
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
